Free Trial
→ Top Trader Reveals Stunning Black Friday Deal (From Base Camp Trading) (Ad)tc pixel Free LFMD Stock Alerts

LifeMD (LFMD) Financials

LifeMD logo
$2.05 +0.40 (+24.11%)
As of 12:22 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for LifeMD

Annual Income Statements for LifeMD

This table shows LifeMD's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -0.46 -0.06 -1.11 -1.21 -1.24 -3.14 -63 -62 -49 -24 -22
Consolidated Net Income / (Loss)		 -0.46 -0.16 -1.22 -1.22 -1.36 -3.53 -61 -61 -45 -18 -19
Net Income / (Loss) Continuing Operations		 -0.56 -0.16 -1.22 -1.38 -2.29 -3.53 -61 -61 -45 -18 -19
Total Pre-Tax Income 		-0.48 -0.17 -1.22 -1.38 -2.41 -3.65 -60 -61 -45 -17 -18
Total Operating Income		 -0.53 -0.26 -1.17 -1.23 -2.06 -2.89 -58 -54 -43 -14 -16
Total Gross Profit		 0.54 0.97 2.05 1.58 6.33 9.94 28 75 100 134 188
Total Revenue		 0.71 1.22 5.24 3.68 8.32 12 37 93 119 153 212
Operating Revenue		 0.71 1.22 5.24 3.68 8.32 12 37 93 119 153 212
Total Cost of Revenue		 0.17 0.25 3.19 2.11 2.00 2.53 8.86 18 19 19 24
Operating Cost of Revenue		 0.17 0.25 3.19 2.11 2.00 2.53 8.86 18 19 19 24
Total Operating Expenses		 1.07 1.23 3.22 2.80 8.38 13 86 129 144 148 205
Selling, General & Admin Expense		 0.46 0.45 1.51 1.16 2.81 3.69 47 46 59 66 92
Marketing Expense		 0.06 0.23 1.71 1.64 5.08 8.92 39 83 78 76 103
Research & Development Expense		 0.00 0.02 - - 0.12 0.22 0.45 0.95 2.97 6.06 9.51
Total Other Income / (Expense), net		 -0.05 0.09 -0.05 -0.15 -0.35 -0.76 -2.58 -7.02 -1.21 -2.92 -2.18
Interest Expense		 0.00 0.04 0.05 0.65 0.35 0.00 2.58 3.02 1.21 2.92 2.18
Income Tax Expense		 -0.02 -0.01 - 0.00 -0.12 -0.12 0.12 0.01 0.36 0.43 0.40
Preferred Stock Dividends Declared		 - - - - - 0.00 4.72 0.87 3.11 3.11 3.11
Net Income / (Loss) Attributable to Noncontrolling Interest		 0.00 -0.10 -0.12 -0.01 -0.12 -0.39 -1.88 -0.43 0.51 2.76 0.15
Weighted Average Basic Shares Outstanding		 30.37M 30.81M 33.48M 41.74M 44.19M 9.90M 14.28M 27.01M 30.98M 33.91M 41.20M
Weighted Average Diluted Shares Outstanding		 30.37M 30.81M 33.48M 41.74M 44.19M 9.90M 14.28M 27.01M 30.98M 33.91M 41.20M
Weighted Average Basic & Diluted Shares Outstanding		 30.37M 30.81M 36.90M 41.74M 46.88M 54.14M 25.91M 30.83M 31.89M 40.37M 44.58M

Quarterly Income Statements for LifeMD

This table shows LifeMD's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -4.51 -7.54 -7.65 -5.43 -0.88 -0.96 -2.40 -4.67 -9.65 -7.86 -5.25
Consolidated Net Income / (Loss)		 -3.22 -6.65 -6.84 -4.79 0.23 0.35 -1.11 -3.64 -8.87 -7.08 -4.47
Net Income / (Loss) Continuing Operations		 -3.22 -6.65 -6.84 -4.79 0.23 -1.65 -3.01 -4.57 -8.87 -7.08 -4.47
Total Pre-Tax Income 		-2.79 -6.65 -6.84 -4.55 0.40 -1.65 -3.01 -4.54 -8.87 -7.08 -4.47
Total Operating Income		 -2.17 -6.17 -6.31 -4.00 1.02 -1.18 -2.35 -3.13 -8.93 -7.13 -4.47
Total Gross Profit		 40 40 46 48 55 43 42 41 44 42 36
Total Revenue		 45 44 51 53 64 51 49 48 50 47 45
Operating Revenue		 45 44 51 53 64 51 49 48 50 47 45
Total Cost of Revenue		 5.36 4.60 5.02 5.01 9.43 8.14 6.84 7.06 5.93 5.28 8.25
Operating Cost of Revenue		 5.36 4.60 5.02 5.01 9.43 8.14 6.84 7.06 5.93 5.28 8.25
Total Operating Expenses		 42 46 52 52 54 44 45 44 53 49 41
Selling, General & Admin Expense		 19 19 23 23 26 20 21 19 21 19 20
Marketing Expense		 20 24 26 27 26 22 22 23 30 28 19
Research & Development Expense		 2.00 2.09 2.40 2.61 2.41 1.86 1.82 1.84 1.80 1.79 1.88
Total Other Income / (Expense), net		 -0.62 -0.48 -0.53 -0.56 -0.61 -0.46 -0.66 -1.42 0.06 0.05 -0.00
Interest Expense		 0.62 0.48 0.53 0.56 0.61 0.46 0.66 1.42 -0.06 -0.05 0.00
Income Tax Expense		 - - - 0.23 - 0.00 0.00 0.03 0.00 0.00 0.00
Net Income / (Loss) Discontinued Operations		 - - - - - 1.99 1.89 0.94 0.00 0.00 0.00
Preferred Stock Dividends Declared		 0.78 0.78 0.78 0.78 0.78 0.78 0.78 0.78 0.78 0.78 0.78
Net Income / (Loss) Attributable to Noncontrolling Interest		 0.51 0.12 0.04 -0.13 0.34 0.53 0.51 0.25 0.00 0.00 0.00
Basic Earnings per Share		 - - - - - ($0.02) ($0.05) ($0.10) ($0.20) ($0.16) ($0.11)
Weighted Average Basic Shares Outstanding		 33.91M 39.24M 41.30M 42.02M 41.20M 43.14M 44.40M 46.16M 47.34M 47.79M 48.18M
Diluted Earnings per Share		 - - - - - ($0.02) ($0.05) ($0.10) ($0.20) ($0.16) ($0.11)
Weighted Average Diluted Shares Outstanding		 33.91M 39.24M 41.30M 42.02M 41.20M 43.14M 44.40M 46.16M 47.34M 47.79M 48.18M
Weighted Average Basic & Diluted Shares Outstanding		 40.37M 42.29M 43.07M 43.31M 44.58M 45.45M 47.42M 48.14M 48.36M 48.20M 48.33M

Annual Cash Flow Statements for LifeMD

This table details how cash moves in and out of LifeMD's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -0.08 0.16 -0.05 -0.04 0.04 0.21 8.07 32 -37 29 1.86
Net Cash From Operating Activities		 0.03 -0.30 -0.41 -0.82 -0.91 0.25 -12 -33 -23 8.82 18
Net Cash From Continuing Operating Activities		 0.03 -0.30 -0.41 -0.82 -0.87 0.24 -12 -33 -23 8.82 18
Net Income / (Loss) Continuing Operations		 -0.46 -0.16 -1.22 -1.22 -1.36 -3.53 -61 -61 -45 -18 -19
Consolidated Net Income / (Loss)		 -0.46 -0.16 -1.22 -1.22 -1.36 -3.53 -61 -61 -45 -18 -19
Depreciation Expense		 0.06 0.04 - 0.00 - - 0.00 0.01 0.16 0.20 0.49
Amortization Expense		 - 0.00 0.03 0.09 0.51 0.96 1.21 2.95 3.61 6.73 9.41
Non-Cash Adjustments To Reconcile Net Income		 0.26 0.00 0.66 1.49 0.22 0.64 38 17 25 14 14
Changes in Operating Assets and Liabilities, net		 0.18 -0.18 0.12 -1.18 -0.24 2.18 9.46 8.52 -6.37 5.27 12
Net Cash From Investing Activities		 0.00 0.13 0.00 0.00 0.14 -0.10 -0.80 -3.40 -14 -8.73 -12
Net Cash From Continuing Investing Activities		 0.00 0.13 0.00 0.00 0.14 -0.10 -0.80 -3.40 -14 -8.73 -12
Purchase of Property, Plant & Equipment		 - - - - - - 0.00 -0.25 -0.37 -0.20 -1.49
Acquisitions		 - - - 0.00 -0.25 0.00 -0.40 -3.15 -14 -8.53 -10
Net Cash From Financing Activities		 -0.11 0.33 0.36 0.78 0.80 0.78 21 69 -0.53 29 -4.12
Net Cash From Continuing Financing Activities		 -0.11 0.33 0.36 0.78 0.80 0.08 21 69 -0.53 29 -4.12
Repayment of Debt		 -0.08 -0.15 -0.17 -0.76 -0.23 -0.58 -2.51 -16 -0.17 -5.14 -0.33
Payment of Dividends		 0.00 0.18 0.22 0.06 0.16 -0.09 -0.16 -1.02 -3.25 -3.25 -3.88
Issuance of Debt		 0.07 0.31 0.30 0.88 0.88 1.09 2.59 16 2.91 22 0.00
Issuance of Common Equity		 - - - 0.67 0.00 0.35 17 14 0.00 16 0.00
Other Financing Activities, net		 -0.10 0.00 0.09 0.00 0.00 0.00 0.93 0.85 -0.02 -0.52 0.09
Cash Interest Paid		 0.00 0.03 0.01 0.00 0.00 0.08 1.67 0.44 0.19 2.15 2.53

Quarterly Cash Flow Statements for LifeMD

This table details how cash moves in and out of LifeMD's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents		 18 1.96 0.59 1.88 -2.58 -0.61 1.83 -12 -2.31 -9.34 -3.22
Net Cash From Operating Activities		 5.71 5.20 4.54 6.70 1.57 3.07 8.64 -0.15 0.44 -6.93 -0.95
Net Cash From Continuing Operating Activities		 5.71 5.20 4.54 6.70 1.57 0.26 8.64 -0.15 0.44 -6.93 -0.95
Net Income / (Loss) Continuing Operations		 -3.22 -6.65 -6.84 -2.75 0.23 1.65 -1.57 -4.67 8.87 7.08 4.63
Consolidated Net Income / (Loss)		 -3.22 -6.65 -6.84 -2.75 0.23 0.35 -1.57 -4.67 -8.87 -7.08 -4.63
Depreciation Expense		 0.06 0.07 0.10 0.15 0.17 0.16 0.18 0.26 0.29 0.29 0.30
Amortization Expense		 1.98 2.13 2.28 2.51 2.48 1.64 2.74 2.76 1.71 1.75 1.76
Non-Cash Adjustments To Reconcile Net Income		 4.05 2.96 4.55 2.51 4.12 2.82 2.12 5.01 1.65 1.02 1.90
Changes in Operating Assets and Liabilities, net		 2.85 6.69 4.44 4.28 -5.44 -2.71 5.17 -3.51 5.67 -2.90 -0.28
Net Cash From Investing Activities		 -2.22 -2.19 -3.13 -3.49 -2.72 -2.87 -3.70 -3.59 -2.06 -1.63 -1.49
Net Cash From Continuing Investing Activities		 -2.22 -2.19 -3.13 -3.49 -2.72 -2.00 -3.70 -3.59 -2.06 -1.63 -1.49
Purchase of Property, Plant & Equipment		 -0.11 -0.18 -0.64 -0.45 -0.23 -0.12 -0.80 -0.80 -0.11 -0.07 -0.17
Acquisitions		 -2.11 -2.01 -2.49 -3.05 -2.50 -1.89 -2.90 -2.80 -1.95 -1.57 -1.32
Net Cash From Financing Activities		 14 -1.05 -0.82 -1.32 -1.43 -0.81 -3.10 -8.70 -0.70 -0.78 -0.78
Net Cash From Continuing Financing Activities		 14 -1.05 -0.82 -1.32 -1.43 -0.78 -3.10 -8.70 -0.70 -0.78 -0.78
Payment of Dividends		 -0.81 -0.81 -0.81 -1.31 -1.44 -0.78 -1.05 -1.23 -0.78 -0.78 -0.78

Annual Balance Sheets for LifeMD

This table presents LifeMD's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 0.45 0.79 1.26 2.62 3.45 13 50 26 58 76 64
Total Current Assets		 0.45 0.79 1.26 1.61 2.75 12 45 11 43 52 45
Cash & Equivalents		 0.23 0.18 0.14 0.18 1.11 9.18 41 3.96 33 35 37
Accounts Receivable		 0.15 0.45 0.13 0.10 0.10 1.00 0.98 2.83 5.28 11 2.49
Inventories, net		 0.06 0.16 0.68 1.02 0.95 1.26 1.62 3.70 2.76 2.80 2.77
Other Current Assets		 - 0.00 0.02 0.30 0.59 0.97 1.00 0.81 1.42 3.71 2.97
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.23 0.48 0.48 1.48 2.44
Total Noncurrent Assets		 0.00 0.00 0.00 1.01 0.70 0.99 4.77 14 15 22 16
Intangible Assets		 - - 0.00 1.01 0.68 0.72 3.02 13 15 16 11
Other Noncurrent Operating Assets		 - - - 0.00 0.02 0.27 1.75 1.21 0.59 6.40 5.27
Total Liabilities & Shareholders' Equity		 0.45 0.79 1.26 2.62 3.45 13 50 26 58 76 64
Total Liabilities		 0.27 1.15 0.64 1.80 4.58 14 24 33 53 84 45
Total Current Liabilities		 0.27 1.15 0.64 1.19 3.98 14 23 31 35 67 40
Accounts Payable		 0.17 0.75 0.42 0.87 3.05 12 9.06 10 11 16 14
Accrued Expenses		 - - - - - - 12 12 14 23 14
Current Deferred Revenue		 - - 0.00 0.08 0.11 0.92 1.50 5.55 8.83 20 11
Other Current Liabilities		 - 0.19 - - - 0.09 0.61 0.76 0.60 0.51 0.64
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.60 0.60 0.29 1.28 1.60 18 16 5.68
Other Noncurrent Operating Liabilities		 - - 0.00 0.60 0.53 0.29 1.28 1.60 0.21 6.37 5.68
Commitments & Contingencies		 - - - - 0.00 - 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 0.18 -0.36 0.62 0.82 -1.13 -4.48 22 -12 5.57 -7.55 18
Total Preferred & Common Equity		 0.10 -0.36 0.88 0.90 -0.99 -2.30 23 -11 3.51 -9.08 18
Preferred Stock		 - - - - - 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 0.10 -0.36 0.88 0.90 -0.99 -2.30 23 -11 3.51 -9.08 18
Common Stock		 8.69 9.43 12 13 16 78 165 179 218 231 252
Retained Earnings		 -8.59 -9.69 -11 -12 -17 -80 -142 -191 -214 -240 -233
Treasury Stock		 0.00 -0.09 -0.16 -0.16 -0.16 -0.16 -0.16 -0.16 -0.16 -0.16 -0.16

Quarterly Balance Sheets for LifeMD

This table presents LifeMD's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets		 41 61 64 73 74 74 66 70 60 66
Total Current Assets		 25 44 45 49 50 49 41 52 42 49
Cash & Equivalents		 15 35 36 38 34 36 24 34 25 22
Accounts Receivable		 4.42 5.34 5.67 6.05 10 7.33 9.24 9.86 11 13
Inventories, net		 3.79 2.37 2.06 2.65 2.97 3.25 3.43 3.18 2.96 10
Other Current Assets		 1.39 1.59 1.64 2.37 2.42 2.22 4.62 4.19 2.73 3.74
Plant, Property, & Equipment, net		 0.42 0.59 1.12 1.42 1.44 2.05 2.58 2.26 2.04 1.91
Total Noncurrent Assets		 15 16 18 22 22 22 22 16 16 15
Intangible Assets		 15 15 15 16 16 17 17 11 11 10
Other Noncurrent Operating Assets		 0.80 1.67 2.53 6.75 6.10 5.82 5.58 5.06 4.84 4.62
Total Liabilities & Shareholders' Equity		 41 61 64 73 74 74 66 70 60 66
Total Liabilities		 52 60 66 79 74 73 63 55 52 67
Total Current Liabilities		 33 45 52 59 61 64 57 50 47 62
Accounts Payable		 9.64 12 15 16 16 24 20 22 18 38
Accrued Expenses		 15 15 15 21 19 15 22 15 17 13
Current Deferred Revenue		 6.24 13 15 16 15 12 14 12 11 10
Other Current Liabilities		 0.73 0.45 0.34 0.40 0.48 0.54 0.67 0.67 0.70 0.69
Total Noncurrent Liabilities		 19 15 14 20 13 9.65 5.95 5.50 5.32 5.16
Other Noncurrent Operating Liabilities		 0.43 1.41 2.44 6.61 6.29 6.13 5.95 5.50 5.32 5.16
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -11 1.30 -2.06 -5.96 -0.39 0.38 3.37 15 7.97 -0.58
Total Preferred & Common Equity		 -13 -0.85 -4.21 -7.72 -2.33 -1.78 1.31 15 7.97 -0.58
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -13 -0.85 -4.21 -7.72 -2.33 -1.78 1.31 15 7.97 -0.58
Common Stock		 197 221 225 228 233 237 249 253 254 256
Retained Earnings		 -210 -222 -229 -235 -236 -238 -248 -238 -246 -256
Treasury Stock		 -0.16 -0.16 -0.16 -0.16 -0.16 -0.16 -0.16 -0.16 -0.16 -0.16

Annual Metrics And Ratios for LifeMD

This table displays calculated financial ratios and metrics derived from LifeMD's official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -11.65% 70.67% 329.79% -29.72% 126.09% 49.79% 199.10% 149.04% 28.16% 28.15% 39.27%
EBITDA Growth		 -84.82% 47.49% -422.26% 44.44% -143.63% -74.35% -2,002.00% 2.24% 28.30% 80.96% 17.26%
EBIT Growth		 -67.69% 44.56% -347.98% 38.24% -183.40% -77.55% -1,483.77% -0.83% 25.47% 66.65% -11.43%
NOPAT Growth		 2.84% 50.61% -347.98% -4.57% -67.39% -40.54% -1,900.94% 6.09% 19.99% 66.65% -11.43%
Net Income Growth		 -71.65% 65.42% -668.25% 0.40% -11.62% -159.41% -1,615.42% -1.32% 26.59% 60.38% -4.99%
EPS Growth		 -100.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 112.91% -982.57% -38.22% -100.34% -10.81% 127.76% -4,925.47% -172.72% 30.68% 138.46% 98.56%
Free Cash Flow Firm Growth		 62.93% -192.45% -4.05% -266.99% -20.07% 114.85% -11,545.49% 2.71% -17.63% 75.17% 101.02%
Invested Capital Growth		 -564.48% 125.56% -803.91% 219.44% 119.79% -260.21% -548.90% -67.49% 45.18% -10.13% -122.20%
Revenue Q/Q Growth		 -0.12% 21.26% 13.24% -4.75% 19.92% 16.43% 31.57% 18.54% 0.59% 12.33% 10.05%
EBITDA Q/Q Growth		 32.44% -178.94% -56.03% 45.25% -0.11% -40.51% -130.81% 21.22% 9.54% 54.37% 37.78%
EBIT Q/Q Growth		 29.69% -92.36% -59.33% 42.75% -15.77% -29.32% -122.29% 20.10% 7.05% 36.14% 16.50%
NOPAT Q/Q Growth		 21.09% -92.36% -59.33% 30.36% -15.77% -2.36% -122.29% 25.58% 7.05% 36.14% 16.50%
Net Income Q/Q Growth		 -18.71% -2.48% -94.10% 31.13% -16.27% -10.89% -119.84% 20.40% 12.50% 31.89% 15.58%
EPS Q/Q Growth		 0.00% 0.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 124.12% -438.35% -24.93% -33.55% 8.60% 177.64% -123.15% 2.10% 14.40% 675.36% -19.14%
Free Cash Flow Firm Q/Q Growth		 59.77% -275.90% 46.63% -43.94% 1.92% 151.19% -179.10% 29.32% 13.43% 19.38% -97.98%
Invested Capital Q/Q Growth		 -56.02% 146.06% -271.31% 437.85% 11.97% -126.96% -29.39% -16.78% -207.46% -30.99% 18.14%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 75.80% 79.67% 39.04% 42.80% 76.02% 79.75% 76.24% 80.62% 84.32% 87.61% 88.67%
EBITDA Margin		 -58.25% -17.92% -21.78% -17.22% -18.55% -21.60% -151.78% -59.58% -33.33% -4.95% -2.94%
Operating Margin		 -74.34% -21.51% -22.42% -33.36% -24.70% -23.18% -155.04% -58.47% -36.50% -9.50% -7.60%
EBIT Margin		 -66.23% -21.51% -22.42% -19.71% -24.70% -29.28% -155.04% -62.77% -36.50% -9.50% -7.60%
Profit (Net Income) Margin		 -64.48% -13.06% -23.35% -33.09% -16.34% -28.30% -162.29% -66.03% -37.82% -11.69% -8.82%
Tax Burden Percent		 96.40% 92.34% 100.00% 88.34% 56.42% 96.64% 100.20% 100.01% 100.81% 102.46% 102.19%
Interest Burden Percent		 100.99% 65.76% 104.14% 190.11% 117.24% 100.00% 104.47% 105.18% 102.79% 120.17% 113.51%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% -2,618.30% -223.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% -2,251.32% -327.31% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 1,685.03% 34.47% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -1,644.91% -767.53% 1,353.69% -933.27% -188.56% 2,279.95% 6,204.43% -490.64% -486.36% 2,051.24% -2,462.99%
Cash Return on Invested Capital (CROIC)		 0.00% -873.54% 0.00% -396.77% -297.95% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -130.18% -84.09% -189.73% -70.66% -105.99% -120.44% -686.32% -184.12% -114.96% -34.44% -24.66%
Return on Assets (ROA)		 -126.74% -51.06% -197.58% -118.66% -70.11% -116.40% -718.43% -193.68% -119.12% -42.40% -28.61%
Return on Common Equity (ROCE)		 -1,644.91% 729.20% 1,910.61% -1,882.71% -232.62% 666.56% 10,462.86% -401.15% -298.01% 9,305.63% 3,207.37%
Return on Equity Simple (ROE_SIMPLE)		 330.10% -159.11% 344.42% -138.16% -151.51% 357.04% 2,629.32% -269.67% 395.07% -508.91% 341.42%
Net Operating Profit after Tax (NOPAT)		 -0.37 -0.18 -0.82 -0.86 -1.44 -2.02 -40 -38 -30 -10 -11
NOPAT Margin		 -52.04% -15.06% -15.70% -23.35% -17.29% -16.22% -108.53% -40.93% -25.55% -6.65% -5.32%
Net Nonoperating Expense Percent (NNEP)		 -87.41% 26.83% -734.60% -366.98% 104.28% -1,340.83% -461.37% -93.88% -68.86% -95.89% -47.06%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - - -42.58% -79.12%
Cost of Revenue to Revenue		 24.20% 20.33% 60.96% 57.20% 23.98% 20.25% 23.76% 19.38% 15.68% 12.39% 11.33%
SG&A Expenses to Revenue		 63.85% 36.62% 28.82% 31.58% 33.70% 29.62% 125.36% 49.20% 49.32% 43.02% 43.30%
R&D to Revenue		 0.00% 1.96% 0.00% 0.00% 1.45% 1.79% 1.20% 1.02% 2.50% 3.97% 4.48%
Operating Expenses to Revenue		 150.13% 101.19% 61.47% 76.16% 100.72% 102.92% 231.28% 139.09% 120.82% 97.11% 96.27%
Earnings before Interest and Taxes (EBIT)		 -0.47 -0.26 -1.17 -0.73 -2.06 -3.65 -58 -58 -43 -14 -16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -0.42 -0.22 -1.14 -0.63 -1.54 -2.69 -57 -55 -40 -7.56 -6.25
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 10.51 0.00 0.00 5.21 0.00 89.82 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 1.13 0.49 3.44 1.27 0.51 2.06 1.01
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 10.63 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 1.13 0.46 3.25 0.86 0.54 1.98 0.94
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 22.71 0.00 0.00 0.00 34.24 11.37
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 20.00 0.00 0.00 0.00 0.00 2,112.60
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -0.20 0.55 -0.57 0.27 0.30 -0.72 -0.95 0.00 -0.38 3.28 -4.53
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.22 -2.44
Financial Leverage		 -3.63 -4.37 0.60 -0.75 -0.11 0.73 4.46 -1.99 -2.29 9.23 -20.76
Leverage Ratio		 12.98 15.03 -6.85 7.86 2.69 -19.59 -8.64 2.53 4.08 -48.38 86.10
Compound Leverage Factor		 13.11 9.88 -7.14 14.95 3.15 -19.59 -9.02 2.66 4.20 -58.13 97.74
Debt to Total Capital		 -24.22% 35.59% -132.83% 21.19% 23.18% -259.05% -1,827.58% 0.25% -62.05% 76.63% 128.32%
Short-Term Debt to Total Capital		 -24.22% 35.59% -132.83% 21.19% 23.18% -259.05% -1,827.58% 0.25% -62.05% 1.38% 59.12%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 75.26% 69.20%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 28.80% 4.22% -32.78% -7.31% 44.85% -3,471.89% 11.90% -90.73% 8.65% 10.08%
Common Equity to Total Capital		 124.22% 35.62% 228.61% 111.59% 84.12% 314.20% 5,399.46% 87.86% 252.78% 14.71% -38.40%
Debt to EBITDA		 -0.07 -0.46 -0.18 -0.26 -0.16 -0.30 -0.01 0.00 -0.07 -2.42 -2.93
Net Debt to EBITDA		 0.12 0.61 -0.02 -0.04 -0.04 0.11 0.15 0.75 0.03 1.97 2.67
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -2.37 -1.58
Debt to NOPAT		 -0.07 -0.54 -0.25 -0.19 -0.17 -0.40 -0.02 0.00 -0.09 -1.80 -1.62
Net Debt to NOPAT		 0.13 0.72 -0.03 -0.03 -0.05 0.14 0.21 1.09 0.04 1.47 1.48
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.77 -0.87
Altman Z-Score		 0.00 0.00 0.00 0.00 -2.57 -6.24 -14.56 -2.49 -11.17 0.39 -0.88
Noncontrolling Interest Sharing Ratio		 0.00% 195.01% -41.14% -101.73% -23.36% 70.76% -68.64% 18.24% 38.73% -353.66% 230.22%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.44 1.68 0.69 1.97 1.35 0.69 0.89 1.97 0.36 1.22 0.81
Quick Ratio		 0.30 1.45 0.55 0.42 0.23 0.30 0.73 1.85 0.22 1.10 0.72
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -0.14 -0.42 -0.44 -1.60 -1.92 0.29 -33 -32 -37 -9.28 0.09
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -13,375.17% -6,255.62% 4,327.59% 1,174.71%
Free Cash Flow to Firm to Interest Expense		 -30.62 -11.19 -8.98 -2.45 -5.43 0.00 -12.65 -10.53 -30.84 -3.18 0.04
Operating Cash Flow to Interest Expense		 7.14 -7.88 -8.39 -1.25 -2.56 0.00 -4.70 -10.96 -18.91 3.02 8.03
Operating Cash Flow Less CapEx to Interest Expense		 7.14 -7.88 -8.39 -1.25 -1.45 0.00 -4.70 -11.04 -19.22 2.95 7.34
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 1.97 3.91 8.46 3.59 4.29 4.11 4.43 2.93 3.15 3.63 3.25
Accounts Receivable Turnover		 15.45 14.39 17.42 12.80 73.26 126.91 68.10 93.92 62.41 37.61 31.49
Inventory Turnover		 2.72 4.86 28.86 5.01 2.34 2.56 8.00 12.49 7.02 5.85 8.66
Fixed Asset Turnover		 9.89 0.00 0.00 0.00 0.00 0.00 0.00 0.00 335.19 320.23 217.29
Accounts Payable Turnover		 0.75 1.12 6.94 3.58 3.09 1.29 1.17 1.70 1.95 1.78 1.78
Days Sales Outstanding (DSO)		 23.62 25.37 20.95 28.51 4.98 2.88 5.36 3.89 5.85 9.70 11.59
Days Inventory Outstanding (DIO)		 134.30 75.17 12.65 72.92 155.77 142.56 45.60 29.22 52.01 62.41 42.14
Days Payable Outstanding (DPO)		 485.34 325.41 52.60 101.84 118.06 283.30 312.94 215.03 187.37 204.62 205.44
Cash Conversion Cycle (CCC)		 -327.42 -224.88 -19.00 -0.41 42.70 -137.87 -261.97 -181.92 -129.51 -132.51 -151.71
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -0.19 0.05 -0.34 0.40 0.89 -1.42 -9.22 -15 -8.47 -9.33 -21
Invested Capital Turnover		 -9.69 -17.44 -36.14 112.11 12.90 -46.69 -7.01 -7.53 -9.96 -17.15 -14.14
Increase / (Decrease) in Invested Capital		 -0.23 0.24 -0.39 0.74 0.48 -2.31 -7.80 -6.22 6.98 -0.86 -11
Enterprise Value (EV)		 0.00 0.00 0.00 0.00 9.43 5.71 121 80 64 302 199
Market Capitalization		 0.00 0.00 0.00 0.00 9.44 6.14 128 118 61 315 214
Book Value per Share		 $0.00 $0.00 ($0.01) $0.02 $0.02 ($0.02) ($0.12) $0.74 ($0.36) $0.09 ($0.13)
Tangible Book Value per Share		 $0.00 $0.00 ($0.01) $0.02 $0.00 ($0.03) ($0.15) $0.64 ($0.77) ($0.30) ($0.49)
Total Capital		 -0.11 0.28 -0.16 0.79 1.07 -0.31 -0.04 26 -4.51 24 14
Total Debt		 0.03 0.10 0.21 0.17 0.25 0.81 0.78 0.06 2.80 18 18
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 18 9.89
Net Debt		 -0.05 -0.13 0.02 0.03 0.07 -0.29 -8.40 -41 -1.16 -15 -17
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 -0.39 0.00 0.00 0.25 0.37 0.20 1.49
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.22 0.05 -0.34 0.65 0.48 -1.52 -9.92 -19 -21 -25 -38
Debt-free Net Working Capital (DFNWC)		 -0.14 0.28 -0.16 0.79 0.66 -0.41 -0.74 22 -17 8.15 -3.08
Net Working Capital (NWC)		 -0.17 0.18 -0.36 0.62 0.41 -1.23 -1.52 22 -20 7.82 -12
Net Nonoperating Expense (NNE)		 0.09 -0.02 0.40 0.36 -0.08 1.51 20 23 15 7.70 7.43
Net Nonoperating Obligations (NNO)		 -0.05 -0.13 0.02 -0.22 0.07 -0.29 -8.40 -41 -1.16 -15 -17
Total Depreciation and Amortization (D&A)		 0.06 0.04 0.03 0.09 0.51 0.96 1.21 2.96 3.77 6.93 9.89
Debt-free, Cash-free Net Working Capital to Revenue		 -30.57% 3.94% -6.45% 17.63% 5.77% -12.19% -26.60% -20.64% -17.83% -16.39% -17.93%
Debt-free Net Working Capital to Revenue		 -20.00% 23.05% -2.97% 21.47% 7.93% -3.32% -1.99% 23.86% -14.50% 5.34% -1.45%
Net Working Capital to Revenue		 -23.81% 14.85% -6.91% 16.92% 4.96% -9.85% -4.07% 23.79% -16.85% 5.13% -5.42%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.02) $0.00 ($0.03) ($0.03) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 30.73M 32.01M 33.48M 41.74M 44.19M 49.49M 14.28M 27.01M 30.98M 33.91M 41.20M
Adjusted Diluted Earnings per Share		 ($0.02) $0.00 ($0.03) ($0.03) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 30.73M 32.01M 33.48M 41.74M 44.19M 49.49M 14.28M 27.01M 30.98M 33.91M 41.20M
Adjusted Basic & Diluted Earnings per Share		 ($0.02) $0.00 ($0.03) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 30.37M 30.81M 36.90M 41.74M 46.88M 54.14M 25.91M 30.83M 31.89M 40.37M 44.58M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.37 -0.18 -0.82 -0.86 -1.44 -2.02 -40 -38 -24 -10 -11
Normalized NOPAT Margin		 -52.04% -15.06% -15.70% -23.35% -17.29% -16.22% -108.53% -40.93% -20.34% -6.65% -5.32%
Pre Tax Income Margin		 -66.89% -14.15% -23.35% -37.46% -28.96% -29.28% -161.96% -66.02% -37.52% -11.41% -8.63%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -101.00 -7.00 -24.16 -1.11 -5.80 0.00 -22.39 -19.31 -35.83 -4.96 -7.40
NOPAT to Interest Expense		 -79.35 -4.90 -16.92 -1.32 -4.06 0.00 -15.67 -12.59 -25.08 -3.47 -5.18
EBIT Less CapEx to Interest Expense		 -101.00 -7.00 -24.16 -1.11 -4.70 0.00 -22.39 -19.39 -36.13 -5.03 -8.08
NOPAT Less CapEx to Interest Expense		 -79.35 -4.90 -16.92 -1.32 -2.96 0.00 -15.67 -12.67 -25.38 -3.54 -5.86
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 111.88% 17.98% 5.20% 11.49% -2.52% -0.26% -1.66% -7.22% -18.22% -20.72%
Augmented Payout Ratio		 0.00% 105.10% 10.86% -1.09% 11.49% -2.52% -0.26% -1.66% -7.22% -18.22% -20.72%

Quarterly Metrics And Ratios for LifeMD

This table displays calculated financial ratios and metrics derived from LifeMD's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding		 37,978,804.00 40,366,047.00 42,289,990.00 43,068,867.00 - 44,583,688.00 45,447,604.00 47,417,393.00 48,135,885.00 48,362,510.00 48,200,837.00
DEI Adjusted Shares Outstanding		 37,978,804.00 40,366,047.00 42,289,990.00 43,068,867.00 - 44,583,688.00 45,447,604.00 47,417,393.00 48,135,885.00 48,362,510.00 48,200,837.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.12 -0.19 -0.18 -0.13 - -0.02 -0.06 -0.10 -0.20 -0.16 -0.11
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 59.53% 33.26% 40.94% 37.96% 43.23% 15.28% 22.81% 12.95% -1.42% -3.55% -6.50%
EBITDA Growth		 98.57% -174.94% -21.44% 51.40% 2,911.96% 115.36% 151.49% 178.87% -1,236.28% -1,004.15% -98.62%
EBIT Growth		 79.06% -116.32% -28.80% 12.54% 146.89% 80.85% 85.62% 50.72% -655.60% -203.79% -42.85%
NOPAT Growth		 79.06% -116.32% -28.80% 12.54% 166.99% 80.85% 85.62% 50.72% -655.60% -203.79% -42.85%
Net Income Growth		 72.16% -93.14% -16.05% 9.38% 107.28% 105.23% 77.04% 25.71% -2,649.11% -535.57% -22.80%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -900.00% -220.00% -10.00%
Operating Cash Flow Growth		 390.17% 299.02% -2.25% 522.36% -72.55% -41.02% 90.31% -102.20% -85.51% -180.16% -545.41%
Free Cash Flow Firm Growth		 95.35% 209.75% 1,597.62% 1,219.76% 1,975.07% -101.80% -98.48% -140.75% -2,178.51% -813.24% 85.28%
Invested Capital Growth		 -10.13% -330.41% -150.34% -255.57% -122.20% -4.39% -3.81% 19.34% -18.86% 15.68% -10.21%
Revenue Q/Q Growth		 16.18% -1.60% 14.76% 5.15% 20.34% -20.80% -5.30% -3.29% 0.00% -5.75% -5.62%
EBITDA Q/Q Growth		 95.27% -2,946.48% 1.38% 65.82% 280.69% -83.36% -61.95% -47.64% 0.00% 26.56% 52.75%
EBIT Q/Q Growth		 52.48% -184.19% -2.18% 36.62% 121.73% -216.05% -135.66% -117.17% 0.00% 20.15% 37.35%
NOPAT Q/Q Growth		 52.48% -184.19% -2.18% 36.62% 131.04% -181.24% -124.96% -117.17% 0.00% 20.15% 37.35%
Net Income Q/Q Growth		 39.01% -106.35% -2.83% 29.98% 104.28% 48.31% -181.90% -126.57% 0.00% 20.16% 36.90%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 20.00% 31.25%
Operating Cash Flow Q/Q Growth		 430.90% -8.95% -12.73% 47.54% -74.72% 95.64% 181.56% -101.70% 0.00% -1,657.64% 86.29%
Free Cash Flow Firm Q/Q Growth		 -156.75% 1,264.25% -4.39% 108.93% -16.76% -101.12% -96.53% -5,701.94% 0.00% -158.54% 87.26%
Invested Capital Q/Q Growth		 -30.99% -68.02% -25.23% -29.01% 18.14% 21.06% -24.53% -0.24% 0.00% 11.66% -31.01%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 88.06% 89.58% 90.08% 90.59% 85.32% 84.01% 88.06% 87.69% 88.19% 88.82% 81.51%
EBITDA Margin		 -0.29% -9.00% -7.73% -2.51% 5.71% 1.20% 3.24% 1.76% -13.82% -10.77% -5.39%
Operating Margin		 -4.84% -13.98% -12.45% -7.50% 1.58% -2.32% -1.46% -3.27% -17.80% -15.08% -10.01%
EBIT Margin		 -4.84% -13.98% -12.45% -7.50% 1.58% -2.32% -1.46% -3.27% -17.80% -15.08% -10.01%
Profit (Net Income) Margin		 -7.18% -15.06% -13.50% -8.99% 0.37% 0.68% -2.52% -5.91% -17.69% -14.98% -10.02%
Tax Burden Percent		 115.32% 100.00% 100.00% 105.10% 58.07% -21.15% 100.00% 104.99% 100.00% 100.00% 100.00%
Interest Burden Percent		 128.67% 107.74% 108.43% 113.98% 39.69% 139.23% 173.12% 172.02% 99.37% 99.36% 100.07%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 2,051.24% 694.33% 358.62% 252.31% -2,462.99% -2,589.27% 583.82% 283.35% 0.00% 0.00% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -17.55% -47.97% -44.71% -25.56% 5.14% -7.54% -5.21% -11.93% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -26.04% -51.69% -48.47% -30.62% 1.19% 2.22% -9.02% -21.54% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 9,305.63% 1,472.15% 591.48% 301.94% 3,207.37% 9,070.31% 2,084.87% 701.66% 0.00% 0.00% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 2,489.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.52 -4.32 -4.41 -2.80 1.02 -0.83 -0.63 -1.38 -6.25 -4.99 -3.13
NOPAT Margin		 -3.39% -9.79% -8.71% -5.25% 1.58% -1.63% -1.02% -2.29% -12.46% -10.56% -7.01%
Net Nonoperating Expense Percent (NNEP)		 -21.21% -35.17% -31.90% -25.86% -4.96% 7.14% -4.88% -10.10% -10.40% -9.12% -5.88%
Return On Investment Capital (ROIC_SIMPLE)		 -6.38% -22.22% -27.45% -22.79% 7.13% -4.59% -4.00% -40.93% -41.57% -62.65% 539.38%
Cost of Revenue to Revenue		 11.94% 10.42% 9.92% 9.41% 14.68% 15.99% 11.94% 12.31% 11.81% 11.18% 18.49%
SG&A Expenses to Revenue		 43.00% 44.07% 45.72% 43.23% 39.75% 38.91% 38.29% 37.25% 42.85% 40.82% 45.85%
R&D to Revenue		 4.45% 4.73% 4.74% 4.90% 3.75% 3.65% 4.41% 4.73% 3.58% 3.79% 4.22%
Operating Expenses to Revenue		 92.90% 103.56% 102.53% 98.09% 83.74% 86.33% 89.51% 90.96% 105.99% 103.90% 91.52%
Earnings before Interest and Taxes (EBIT)		 -2.17 -6.17 -6.31 -4.00 1.02 -1.18 -0.91 -1.97 -8.93 -7.13 -4.47
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -0.13 -3.97 -3.92 -1.34 3.67 0.61 2.02 1.06 -6.93 -5.09 -2.41
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 89.82 0.00 0.00 0.00 0.00 0.00 0.00 244.99 11.56 25.07 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 44.28 0.00 0.00
Price to Revenue (P/Rev)		 2.06 2.54 1.63 1.17 1.01 1.11 2.52 1.28 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 1.98 2.45 1.54 1.08 0.94 1.04 2.45 1.19 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 67.05 26.45 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 34.24 24.05 16.62 9.39 11.37 14.86 30.82 23.76 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 40.46 2,112.60 0.00 0.00 0.00 45.15 0.00 56.56
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 3.28 13.97 -8.81 -3.06 -4.53 -46.92 40.48 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 3.22 10.83 -5.73 -2.17 -2.44 -17.36 9.20 0.00 0.00 0.00 0.00
Financial Leverage		 9.23 2.19 1.24 0.90 -20.76 -36.34 22.84 16.68 -3.44 -5.50 -16.39
Leverage Ratio		 -48.38 -15.72 -8.09 -6.65 86.10 149.06 -81.92 -53.56 9.82 15.99 47.43
Compound Leverage Factor		 -62.25 -16.94 -8.78 -7.58 34.18 207.54 -141.81 -92.13 9.75 15.88 47.47
Debt to Total Capital		 76.63% 93.32% 112.81% 148.52% 128.32% 102.18% 97.59% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 1.38% 20.95% 39.46% 43.00% 59.12% 64.37% 75.41% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 75.26% 72.36% 73.34% 105.52% 69.20% 37.80% 22.18% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.02%
Noncontrolling Interests to Total Capital		 8.65% 11.03% 13.35% 14.38% 10.08% 10.73% 13.65% 60.98% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 14.71% -4.35% -26.16% -62.90% -38.40% -12.91% -11.24% 39.02% 100.00% 100.00% 100.02%
Debt to EBITDA		 -2.42 -1.80 -1.68 -1.95 -2.93 -11.04 1.73 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 1.97 1.68 1.63 2.07 2.67 9.56 -2.32 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -2.37 -1.40 -1.09 -1.38 -1.58 -4.08 0.39 0.00 0.00 0.00 0.00
Debt to NOPAT		 -1.80 -1.46 -1.35 -1.40 -1.62 -2.36 -10.88 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 1.47 1.36 1.31 1.48 1.48 2.04 14.59 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -1.77 -1.13 -0.88 -0.99 -0.87 -0.87 -2.47 0.00 0.00 0.00 0.00
Altman Z-Score		 1.09 1.41 -0.05 -0.51 -0.10 0.23 3.60 1.27 -3.25 -3.93 -4.61
Noncontrolling Interest Sharing Ratio		 -353.66% -112.02% -64.93% -19.67% 230.22% 450.30% -257.11% -147.63% 13.22% 25.93% 73.66%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.22 0.99 0.87 0.83 0.81 0.82 0.77 0.73 1.04 0.90 0.80
Quick Ratio		 1.10 0.91 0.80 0.74 0.72 0.73 0.69 0.58 0.89 0.78 0.57
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -0.66 7.71 7.37 15 12 -0.14 0.11 -6.27 -3.17 -8.18 -1.04
Operating Cash Flow to CapEx		 5,225.94% 2,962.64% 707.07% 1,495.74% 695.78% 2,610.39% 1,085.71% -18.46% 422.73% -10,211.05% -556.23%
Free Cash Flow to Firm to Interest Expense		 -1.06 16.14 13.87 27.56 20.22 -0.30 0.17 -4.42 0.00 0.00 -324.64
Operating Cash Flow to Interest Expense		 9.18 10.89 8.54 11.99 2.55 6.62 13.03 -0.10 0.00 0.00 -295.65
Operating Cash Flow Less CapEx to Interest Expense		 9.00 10.52 7.33 11.19 2.19 6.36 11.83 -0.67 0.00 0.00 -348.81
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 3.63 3.43 3.59 3.41 3.25 3.25 3.57 3.64 0.00 0.00 0.00
Accounts Receivable Turnover		 37.61 39.54 38.19 36.86 31.49 28.23 37.78 33.02 0.00 0.00 0.00
Inventory Turnover		 5.85 6.70 6.86 6.21 8.66 10.34 11.49 10.83 0.00 0.00 0.00
Fixed Asset Turnover		 320.23 312.02 227.43 209.18 217.29 216.51 154.74 126.08 0.00 0.00 0.00
Accounts Payable Turnover		 1.78 2.00 1.60 1.57 1.78 1.97 1.55 1.86 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 9.70 9.23 9.56 9.90 11.59 12.93 9.66 11.06 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 62.41 54.47 53.18 58.75 42.14 35.31 31.77 33.70 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 204.62 182.62 227.59 232.80 205.44 185.60 235.28 196.42 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 -132.51 -118.92 -164.85 -164.15 -151.71 -137.36 -193.86 -151.66 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -9.33 -16 -20 -25 -21 -16 -20 -20 -19 -17 -23
Invested Capital Turnover		 -17.15 -16.94 -12.99 -11.90 -14.14 -13.69 -12.28 -11.04 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -0.86 -12 -12 -18 -11 -0.69 -0.75 4.90 -3.09 3.19 -2.08
Enterprise Value (EV)		 302 400 275 208 199 229 600 300 139 175 118
Market Capitalization		 315 415 290 226 214 243 619 322 174 200 140
Book Value per Share		 $0.09 ($0.02) ($0.10) ($0.18) ($0.13) ($0.05) ($0.04) $0.03 $0.32 $0.16 ($0.01)
Tangible Book Value per Share		 ($0.30) ($0.39) ($0.46) ($0.54) ($0.49) ($0.41) ($0.41) ($0.33) $0.08 ($0.06) ($0.23)
Total Capital		 24 19 16 12 14 18 16 3.37 15 7.97 -0.58
Total Debt		 18 18 18 18 18 18 15 0.00 0.00 0.00 0.00
Total Long-Term Debt		 18 14 12 13 9.89 6.82 3.52 0.00 0.00 0.00 0.00
Net Debt		 -15 -17 -18 -19 -17 -16 -21 -24 -34 -25 -22
Capital Expenditures (CapEx)		 0.11 0.18 0.64 0.45 0.23 0.12 0.80 0.80 0.11 0.07 0.17
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -25 -31 -36 -43 -38 -34 -39 -39 -32 -30 -34
Debt-free Net Working Capital (DFNWC)		 8.15 3.81 -0.23 -5.02 -3.08 0.68 -2.55 -16 2.11 -4.52 -12
Net Working Capital (NWC)		 7.82 -0.27 -6.58 -10 -12 -11 -15 -16 2.11 -4.52 -12
Net Nonoperating Expense (NNE)		 1.70 2.33 2.42 1.99 0.78 -1.18 0.94 2.18 2.62 2.09 1.34
Net Nonoperating Obligations (NNO)		 -15 -17 -18 -19 -17 -16 -21 -24 -34 -25 -22
Total Depreciation and Amortization (D&A)		 2.04 2.20 2.39 2.66 2.65 1.79 2.92 3.03 2.00 2.04 2.06
Debt-free, Cash-free Net Working Capital to Revenue		 -16.39% -19.14% -20.16% -22.08% -17.93% -15.38% -15.79% -15.59% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 5.34% 2.33% -0.13% -2.60% -1.45% 0.31% -1.04% -6.17% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 5.13% -0.16% -3.69% -5.34% -5.42% -4.99% -5.91% -6.17% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($0.20) ($0.16) ($0.11)
Adjusted Weighted Average Basic Shares Outstanding		 33.91M 39.24M 41.30M 42.02M 41.20M 43.14M 44.40M 46.16M 47.34M 47.79M 48.18M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($0.20) ($0.16) ($0.11)
Adjusted Weighted Average Diluted Shares Outstanding		 33.91M 39.24M 41.30M 42.02M 41.20M 45.58M 44.40M 46.16M 47.34M 47.79M 48.18M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 40.37M 42.29M 43.07M 43.31M 44.58M 45.45M 47.42M 48.14M 48.36M 48.20M 48.33M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.52 -4.32 -4.41 -2.80 0.71 -0.83 -0.63 -1.38 -6.25 -4.99 -3.13
Normalized NOPAT Margin		 -3.39% -9.79% -8.71% -5.25% 1.11% -1.63% -1.02% -2.29% -12.46% -10.56% -7.01%
Pre Tax Income Margin		 -6.23% -15.06% -13.50% -8.55% 0.63% -3.23% -2.52% -5.63% -17.69% -14.98% -10.02%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -3.49 -12.92 -11.86 -7.15 1.66 -2.55 -1.37 -1.39 0.00 0.00 -1,390.57
NOPAT to Interest Expense		 -2.44 -9.04 -8.31 -5.01 1.66 -1.78 -0.96 -0.97 0.00 0.00 -973.40
EBIT Less CapEx to Interest Expense		 -3.66 -13.29 -13.07 -7.96 1.29 -2.80 -2.57 -1.95 0.00 0.00 -1,443.72
NOPAT Less CapEx to Interest Expense		 -2.62 -9.41 -9.51 -5.81 1.29 -2.04 -2.16 -1.53 0.00 0.00 -1,026.55
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 -18.22% -15.44% -14.78% -17.42% -20.72% -32.77% -84.16% -110.20% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -18.22% -15.44% -14.78% -17.42% -20.72% -32.77% -84.16% -110.20% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

LifeMD’s Q2 2026 results show improving operating efficiency but worsening cash generation and shareholder profitability. Revenue declined to $47.3 million from $49.0 million in Q2 2025 and $50.2 million in Q1 2026. However, the company reduced total operating expenses to $49.1 million from $53.2 million a year earlier, narrowing its operating loss to $7.1 million from $8.9 million in Q1 and $2.3 million in Q2 2025? Wait, Q2 2025 operating loss was $2.35 million based on the provided restated data. Actually Q2 2026 operating loss was $7.13 million, so it worsened versus Q2 2025 but improved sequentially from $8.93 million.

  • Gross margin improved. Gross profit was $42.0 million in Q2 2026, representing an approximately 88.8% gross margin versus 85.9% in Q2 2025. Cost of revenue also declined to $5.3 million from $6.8 million.
  • Operating expenses fell year over year and sequentially. Total operating expenses declined approximately 7.6% from Q2 2025 and 7.6% from Q1 2026. Marketing expense fell to $28.0 million from $29.9 million in Q2 2025, while SG&A declined to $19.3 million from $21.5 million in Q1.
  • Operating performance improved from the prior quarter. The operating loss narrowed from $8.9 million in Q1 2026 to $7.1 million in Q2, despite the revenue decline.
  • Interest expense is substantially lower than in prior periods. Q2 2026 interest expense was only $45,660, compared with $660,787 in Q2 2025 and $1.4 million in Q3 2025. The balance sheet also shows no reported short-term or long-term debt at June 30, 2026.
  • Balance-sheet equity improved. Total equity increased to $8.0 million at the end of Q2 2026 from $1.3 million in Q3 2025 and a negative $2.1 million at the end of Q2 2025. Total liabilities also declined to $51.9 million from $73.2 million a year earlier.
  • Acquisition spending remains part of the growth strategy. LifeMD spent $1.6 million on acquisitions in Q2 2026, following $2.0 million in Q1 and $2.9 million in Q2 2025. These investments could support future growth, but the financial benefit is not yet evident in quarterly profitability.
  • The company continues to pay preferred dividends. LifeMD paid approximately $776,562 in dividends during Q2 2026 despite reporting a net loss. This supports preferred shareholders but reduces cash available to fund operations and growth.
  • Cash flow deteriorated sharply. Net cash used in operating activities was $6.9 million in Q2 2026, compared with positive operating cash flow of $8.6 million in Q2 2025 and $445,000 in Q1 2026. The decline was driven largely by a $2.9 million unfavorable change in operating assets and liabilities.
  • Cash reserves are declining. Cash and equivalents fell to $25.1 million from $34.5 million at the end of Q1 2026 and $36.2 million at the end of Q2 2025. LifeMD reported a $9.3 million net decrease in cash during Q2.
  • Losses attributable to common shareholders remain significant. Net loss attributable to common shareholders was $7.9 million, or $0.16 per share, compared with a $2.4 million loss, or $0.05 per share, in the restated Q2 2025 period. Weighted-average basic shares increased to 47.8 million from 44.4 million, creating additional dilution for existing investors.

Liquidity remains a key risk. At June 30, 2026, current assets of $42.1 million were below current liabilities of $46.6 million, producing a current ratio of approximately 0.90. Although debt has been reduced and equity has returned to positive territory, the combination of negative operating cash flow, declining cash balances and continued quarterly losses could pressure LifeMD to reduce spending, raise capital or seek other financing if cash generation does not improve.

Overall, the financial statements present a mixed picture: cost control, gross-margin expansion and lower interest expense are encouraging, but these improvements have not yet translated into positive earnings or sustainable free cash flow. Investors should watch whether revenue stabilizes, operating cash flow turns positive and common-shareholder losses narrow in future quarters.

11/13/26 12:22 PM ETAI Generated. May Contain Errors.

LifeMD Financials - Frequently Asked Questions

According to the most recent income statement we have on file, LifeMD's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

LifeMD's net income appears to be on a downward trend, with a most recent value of -$18.73 million in 2024, falling from -$460.49 thousand in 2014. The previous period was -$17.84 million in 2023. Check out LifeMD's forecast to explore projected trends and price targets.

LifeMD's total operating income in 2024 was -$16.14 million, based on the following breakdown:
  • Total Gross Profit: $188.39 million
  • Total Operating Expenses: $204.53 million

Over the last 10 years, LifeMD's total revenue changed from $714.16 thousand in 2014 to $212.45 million in 2024, a change of 29,648.9%.

In the past 12 quarters, LifeMD's cash and equivalents has ranged from $15.29 million in Q3 2023 to $37.59 million in Q3 2024, and is currently $21.92 million as of their latest financial filing in Q3 2026.

LifeMD had total debt of $18.33 million at the end of 2024, a 0.4% increase from 2023, and a 67,287.9% increase since 2014.

Over the last 10 years, LifeMD's book value per share changed from 0.00 in 2014 to -0.13 in 2024, a change of -2,715.6%.


Related Companies

Financial statements for NASDAQ:LFMD last updated on 11/12/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...
Base Camp Trading | Sponsoredtc pixel
Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a...
Traders Agency | Sponsoredtc pixel
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...
Behind the Markets | Sponsoredtc pixel
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
Uranium Mine Flood That Sparked a 2006 Price Surge Returns
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...
Digest Publishing | Sponsoredtc pixel
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...
Weiss Ratings | Sponsoredtc pixel
My next big call (under $1)
17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...
Crypto 101 Media | Sponsoredtc pixel